Sex Differences in Trauma, Inflammation and Brain Function and the Implications for Treatment Efficacy in Alcohol Use Disorder

Alcohol Use Disorder Clinical Trial

— ABSTAIN  

Official title:

Sex Differences in Trauma, Inflammation and Brain Function and the Implications for Treatment Efficacy in Alcohol Use Disorder

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06426303
• Other study ID #: 25536
• Status: Recruiting
• Phase: Phase 4
• Start date: June 1, 2024
• Est. completion date: December 31, 2028

Study information

• Verified date: May 2024
• Source: Oregon Health and Science University
• Contact: Jazryn Nagum
• Phone: 503-721-7964
• Email: vhaporhoffmanlab[@]va.gov
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to identify sex-specific biomarkers that confer greater susceptibility for Alcohol Use Disorder (AUD) and differentiate how treatment response varies by sex in people with Alcohol Use Disorder.

The main questions it aims to answer are:

• How does trauma affect emotion regulation, inflammation, and limbic function, and what are the sex-dependent effects of NTX (Naltrexone) on these aspects?

• What is the mechanism of Naltrexone (NTX), and how does it potentially moderate reductions in alcohol use through changes in or interactions between emotion regulation, inflammation, or limbic system function?

Participants will

• Be consented and will undergo comprehensive screening for eligibility criteria

• Complete behavioral assessments and neuropsychological assessments, as well as neurocognitive assessments and neuroimaging measures

• Provide urine samples for a urine drug screen (UDS) and urine pregnancy test (for women), and have blood and a cheek swab collected and stored in the repository

• Take a study drug once daily for 12 weeks and track drug usage and effects in a study journal

• Undergo weekly assessment calls and bi-weekly medical follow-up safety exams

Researchers will compare naltrexone to placebo in AUD to see if naltrexone is effective in reducing alcohol cravings and promoting abstinence.

Researchers will also compare baseline measures between AUD and Healthy Controls.

Description:

A twelve-week randomized placebo-controlled trial of naltrexone (NTX) will be conducted in one hundred people with alcohol use disorder (AUD), fifty of which will be women. Fifty healthy participants will serve as controls for baseline measures. We will use validated measures to comprehensively assess trauma exposure including: military sexual trauma (MST), physical or sexual assault, combat exposure, intimate partner violence, and other traumatic events. Emotion regulation will be assessed with the Cognitive Emotion Regulation questionnaire and Difficulty in Emotion Regulation scale. Functional magnetic resonance imaging at rest and during an emotion regulation task will assess limbic system connectivity and reactivity. Inflammation will be indexed with a multiplex panel assay of peripheral inflammatory markers. Days of alcohol use and average weekly standard drinks will be assessed at each time-point.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: December 31, 2028
• Est. primary completion date: December 31, 2028
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• 18-60 years old

• Veteran enrolled in VHA healthcare

Alcohol Group:

• must meet diagnosis for recent alcohol-use disorder (DSM-V)

• willing to return for follow-up visits and can participate for 12-weeks

Control Group:

• must not meet DSM-V criteria for a use disorder other than nicotine

Exclusion Criteria:

• Clinically significant neurological, endocrine, hepatic, or systemic disease that would compromise safe participation or confound outcomes

• Left-handedness

• Axis-1 psychiatric diagnoses other than anxiety, depression or post-traumatic stress disorder

• Recreational or prescriptive use of psychotropic medications

• Recreational or prescriptive use of opioid medications or have a past or current history of abuse or dependence on opioids

• MRI contraindications (e.g. metal in body)

• Positive urine drug screen, except for nicotine and marijuana, on test days

• Women who are pregnant or breastfeeding

• Participants on hormonal therapy or treatments other than pregnancy contraceptives

• Autoimmune or neurodegenerative diseases that present with neuroinflammation (multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's, Parkinson's)

• Current participation in an investigational drug study

• Alcohol group: < 5 days and > 3 weeks of abstinence from alcohol

• Alcohol group: Liver disease requiring medication or medical treatment, and/or aspartate or alanine aminotransferase levels greater than 3 times the upper limit of normal, gastrointestinal or renal disease that would significantly impair absorption, metabolism or excretion of study drug, or require medical treatment.

• Non-english speaker

Related Conditions & MeSH terms

• Alcohol Drinking
• Alcohol Use Disorder
• Alcoholism
• Inflammation

Intervention

Drug:
• Naltrexone
12-week randomized double blinded placebo-controlled drug trial titrating drug/placebo dose after 1 week.

Locations

Country	Name	City	State
United States	VA Portland Health Care System	Portland	Oregon

Sponsors (2)

Lead Sponsor	Collaborator
Milky Kohno	Portland VA Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in alcohol use (number of drinking days, amount used per day)	Drinking days and average number of weekly standard drinks will be measured at baseline and at follow-up	Baseline and Week 12
Primary	Changes from baseline in peripheral immune biomarkers associated with inflammation	Plasma samples will be analyzed using a customized, high-sensitivity magnetic bead multiplex assay Luminex system. Samples will be prepared and analyzed to measure peripheral immune markers: interleukin (IL)-1-beta, IL-6, IL-10, tumor necrosis factor (TNF)-alpha, brain-derived neurotrophic factor (BDNF), monocyte chemotactic protein (MCP)-1 and neural cell adhesion molecule (NCAM). Intra-and inter-assay coefficients of variation, as indices of within-and between-assay precision, respectively, will be calculated to examine the reliability of cytokine measurements.	Baseline and Week 12
Primary	Changes in limbic functional connectivity	Resting-state functional magnetic resonance imaging (rs-fMRI) will be used to assess changes in limbic system connectivity. Correlation coefficients of low-frequency oscillations in the fMRI blood oxygenation level dependent (BOLD) signal between regions and between large-scale resting-state networks in the brain will be z-score transformed. A score of 0 indicates no change while higher or lower scores indicate increased or decreased connectivity, respectively.	Baseline and Week 12
Primary	Changes from baseline in BOLD signal brain activation during an emotion regulation fMRI task	The task will assess emotional reactivity and regulation to negative and stressful images. Each event (cue, neutral-look, negative-look, negative-reappraise and rating scale of negative affect) will be modeled using a canonical hemodynamic response function with a time derivative. The contrasts of interest will be Negative-look vs Neutral-look and Negative-look vs Negative-reappraise. Amygdala BOLD signal estimates will be extracted to calculate percent-change.	Baseline and Week 12
Primary	Changes from baseline in emotion regulation assessed with the Difficulty in Emotion Regulation Scale (DERS)	DERS is a 36-item self-report questionnaire scored on a 5-point scale from 1 (almost never) to 5 (almost always), with total score ranging from 36 to 180. It measures emotion regulation difficulties across six dimensions: 1. Non-acceptance of emotional responses, 2. Difficulties engaging in goal-directed behavior, 3. Impulse control difficulties, 4. Lack of emotional awareness, 5. Limited access to effective emotion regulation strategies, 6. Lack of emotional clarity. Higher scores suggest greater difficulties in emotion regulation.	Baseline and Week 12
Primary	Changes from baseline in emotion regulation assessed with the Cognitive Emotion Regulation Questionnaire (CERQ)	CERQ is a 36-item self-report questionnaire that identifies cognitive emotion regulation or cognitive coping strategies used after having experienced negative events or situations. Scores can identify individual strategies to compare with normed scores from various populations. The nine cognitive emotion regulation strategies are measured on a 5-point Likert scale ranging from 1 to 5, with scores being obtained by calculating the mean scores belonging to a particular subscale. Higher subscale scores indicate greater use of a specific cognitive strategy.	Baseline and Week 12
Secondary	Change from baseline in craving (include craving measures/questionnaires)	The Brief Alcohol Craving Scale, a 10-item self-report assessment of craving, will be used. Participants will be prompted with a statement regarding alcohol cravings and will choose an answer ranging between "strongly disagree" and "strongly agree."	Baseline and Week 12
Secondary	Differences in baseline trauma exposure (composite score)	Department of Veterans Affairs Military Sexual Trauma Screening consists of two questions used nationally within the Veterans Heath Administration (VHA) to screen for MST. Response options are yes, no, or decline to respond.; Trauma Assessment for Adults (TAA) is a 17-item self-report on combat exposure, physical or sexual assault, surviving serious accidents and other threatening life events.; Life Stressor Checklist-Revised (LSC-R) includes self-report measures relevant to women such as abortion or caregiver duties, in addition to 30 life events related to natural disasters, physical or sexual assault, death of a relative, incarceration and financial hardships.; Childhood Maltreatment questionnaire is 70 items in five dimensions: emotional, physical, and sexual abuse, and physical and emotional neglect. A 7-point scale will be used to indicate level of trauma	Baseline and Week 12
Secondary	Change from baseline in neuropsychological testing scores	The Standard Neuropsychological Battery will be used	Baseline and Week 12